← Back to Clinical Trials
Recruiting NCT06917586

NCT06917586 Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06917586
Status Recruiting
Phase
Sponsor Michael Moront
Condition Valve Disease, Heart
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2025-01-01
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2025-01-01 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.

Eligibility Criteria

Inclusion Criteria: * Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital * Under the age of 65 Exclusion Criteria: * Over the age of 65 * Under the age of 18 * Surgery performed at institutions outside of ProMedica Toledo Hospital

Contact & Investigator

Central Contact

Dawn Muskiewicz, MS

✉ dawn.muskiewicz@promedica.org

📞 419-291-7517

Principal Investigator

Michael Moront, MD

PRINCIPAL INVESTIGATOR

ProMedica Health System

Frequently Asked Questions

Who can join the NCT06917586 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Valve Disease, Heart. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06917586 currently recruiting?

Yes, NCT06917586 is actively recruiting participants. Contact the research team at dawn.muskiewicz@promedica.org for enrollment information.

Where is the NCT06917586 trial being conducted?

This trial is being conducted at Toledo, United States.

Who is sponsoring the NCT06917586 clinical trial?

NCT06917586 is sponsored by Michael Moront. The principal investigator is Michael Moront, MD at ProMedica Health System. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology